Background: The purpose of this study was to determine the predictive value of breast cancer molecular subclassification regarding the benefit of adjuvant anthracycline-based chemotherapy.
introduction
Adjuvant chemotherapy decreases the relapse rates of patients with breast cancer [1] . The Oxford meta-analysis has shown that anthracyclines provide a significant benefit in patients with early breast cancer. Based on this, anthracycline-based chemotherapy, associated or not with taxanes [2] , has become a standard treatment in patients with intermediate and highrisk early breast cancer [3] . However, a large proportion of treated patients do not benefit from this treatment, and the need has emerged to identify predictive biomarkers [4] .
Studies on gene expression profiles have revealed that breast cancer can be considered a heterogeneous entity [5] [6] [7] , and three large molecular subgroups have been proposed: (i) Her2-overexpressing/Estrogen receptor (ER)-negative tumors, (ii) basal-like and (iii) luminal-like breast cancers. More recently, several efforts have been made to classify breast cancers according to immunohistochemistry (IHC) expression [8, 9] . Basal-like breast cancers are characterized by (i) the lack of ER, progesterone receptor (PgR) and Her2 expressions and (ii) cytokeratine (CK) 5/6 and/or epidermal growth factor receptor (EGFr) expressions [5] [6] [7] [8] [9] . The luminal subtype is characterized by ER expression [10] . Several studies have investigated whether some subclass-related biomarkers could be associated with chemotherapy efficacy. ER expression has been reported as predictive factor for the efficacy of an adjuvant methotrexate-or paclitaxel-based chemotherapy [11, 12] . In addition to these studies that did not evaluate efficacy of anthracyclines, several papers have reported that ER expression correlates with resistance to preoperative anthracycline-based chemotherapy [13, 14] . Nevertheless, there is no compelling evidence that ER expression could be predictive for the efficacy of adjuvant anthracycline-based chemotherapy [1] , while this drug family is routinely used. Several studies have investigated the predictive value of Her2 status for the efficacy of anthracyclines [15] [16] [17] [18] . In two out of four studies, Her2 expression was found to be predictive for the benefit of anthracyclines in terms of disease-free survival (DFS) [16, 18] . Until now, no study has evaluated the predictive value of the molecular subclassification regarding the benefit of adjuvant chemotherapy. One study reported a good correlation between the molecular subclassification (determined by DNA microarray) and the efficacy of preoperative anthracyclinebased chemotherapy [19] .
In the present study, we planned to evaluate the predictive values of ER expression, Her2 status and the molecular subclassification regarding the benefit of adjuvant anthracycline-based chemotherapy. In addition, since most of the trials that did not report any predictive value for ER expression used a ligand-binding assay, we compared the value of ER status by IHC and ligand-binding assay to predict efficacy of adjuvant chemotherapy.
patients and methods patients
Two French multicentric randomized trials compared adjuvant anthracycline-based chemotherapy with no chemotherapy in pre-and postmenopausal early breast cancer patients and included a total of 1146 patients, between 1989 and 1995. Nine hundred and thirty-five patients (83% of the trials) were included at the Institut Gustave Roussy (IGR). Inclusion criteria and results of these trials were reported elsewhere [20] . Of the 935 patients, 688 were postmenopausal and presented either with histologically confirmed positive axillary lymph nodes or with negative lymph nodes, but with a tumor grade II or III. The remaining 247 patients were premenopausal and presented with negative axillary nodes, but with a tumor grade II or III. Tumor grade was defined according to a modified Scarff-Bloom-Richardson classification [21] . In the two trials, ER and PgR status were defined according to ligand-binding assay. The cut-off for positivity was defined as 10 fmol/mg protein.
tissue array and immunostaining
Primary tumors from 823 (88%) out of the 935 patients included at the IGR were used to build a tissue array [22] . The tissue array contained three spots of each primary tumor. Each slide was stained with anti-Her2 (DA485, Dako, Glostrub, Denmark), anti-ER (clone 6F11, Novocastra, Newcastle, UK), anti-CK 5/6 (D5/16B4, Zymed, Cergy Pontoise, France) and anti-EGFr (3C6, Ventana, Illkirch, France) antibodies according to manufacturer recommendations. Her2 staining was considered positive when an intense complete membrane staining was observed in >10% of tumor cells. ER staining was considered positive when >10% of tumor cells were stained. CK 5/6 and EGFr stainings were considered positive when observed in at least one tumor cell as previously reported [8] . A staining was also carried out using anti-CK 18 antibody (DC-10, Zymed). CK 18 staining was considered positive when an intense staining was observed in >50% of tumor cells, as used by Abd El-Rehim et al. [10] . In this latter study, authors indicated that luminal tumors had a higher percentage of stained tumor cells as compared with other subtypes. When a discrepancy was observed between the three spots, the definitive score was the one observed in two out of three spots, except for CK 5/6 and EGFr for which a staining was considered positive if one tumor cell was stained in at least one spot.
breast cancer molecular subclassification
Breast tumors were classified into four subclasses according to Her2, ER, CK 5/6 and EGFr expressions. The algorithm for subclassification is summarized in Figure 1 and is derived from Nielsen et al. [8] to classify basal-like tumors. In addition to the Her2+/ER2, basal-like and luminal subclasses, another subclass emerged from this subclassification, i.e. Her22/ER2/nonbasal tumors. This latter subclass was defined by the lack of Her2/ER/CK 5/6 and EGFr expressions IHC. Illustrative stainings are shown in Figure 2 .
treatment and follow-up [19] .
statistical analysis
The primary end point was DFS, defined as the time between the date of randomization and the date of the last follow-up or the date of the best available evidence for the first event: locoregional recurrence, distant metastasis, contralateral breast tumor or death. Survival rates were estimated using the Kaplan-Meier method. The median follow-up was calculated by use of the inverted Kaplan-Meier method [23] . Chi-square tests were used to compare the distribution of clinical characteristics across the five molecular subgroups. We used a Cox model [24] stratified by trial and adjusted for the significant clinical prognostic variables: histological grade (I, II or III), lymph node status (positive or negative) and age (six classes as reported in Table 1 ). The predictive value of the binary variables ER and Her2 status, and the four-class molecular subclassification were studied by testing the interaction between the relevant variables and the attributed treatment (chemotherapy or no chemotherapy) in the same Cox model. The added predictive value of the Her2 status as opposed to ER status alone was tested adding the Her2 · treatment interaction into the adjusted Cox model with the ER · treatment interaction and applying a likelihood ratio test (test with 1 degrees of freedom). This was done analogously for the four-classes subclassification and its interaction with treatment (test with 4 degrees of freedom). The proportional hazard assumptions were verified by tests for interactions between time and the covariates; the data confirmed the proportionality assumption. Two-sided P values of P < 0.05, and of <0.01 for the interaction tests, were considered statistically significant. All analyses were carried out using SAS software, version 8.2 (SAS Institute Inc., Cary, NC).
results patient characteristics
Immunostainings were carried out in the 823 tumors that were retrieved from the 935 patients included in the two randomized trials at IGR. The patients corresponding to the 112 nonretrieved tumors were a bit younger than those corresponding to the 823 retrieved tumors (mean age 54 versus 56, P = 0.02), less postmenopausal (63% versus 75%, P = 0.01) and less progesteron receptor+ (ligand-binding assay, 54% versus 76%, P < 0.001). There was no evidence for a selection bias based on the stage of the disease, tumor grade or ER positivity (ligand-binding assay). The tumor could be successfully classified into the four molecular subclasses for 798 patients. This accounts for 97% of the tumors collected, 85% of the patients included in the trials at the IGR and 70% of the overall population included in the trial. The study flowchart is shown in Figure 1 and patient characteristics are reported in Table 1 . Four hundred (51%) patients were randomized to receive adjuvant anthracycline-based chemotherapy that included epirubicine 50 mg/m2 in 91% of treated patients. predictive value of ER expression regarding the benefit of adjuvant chemotherapy
As shown in Table 2 , ER status, when determined by IHC, was found to be predictive for the benefit of adjuvant chemotherapy in DFS (test for interaction, P = 0.0015). Adjuvant chemotherapy was associated with an adjusted hazard ratio for relapse or death of 0.50 (95% CI: 0.34-0.73) in ER-negative patients and of 1.07 (95% CI: 0.81-1.40) in those with ERpositive disease. The 10-year DFS rates were 69% (95% CI: 61-77) and 49% (95% CI: 40-58) for patients with ER-negative tumors treated or not with adjuvant chemotherapy, respectively ( Figure 3A ). On the other hand, the 10-year DFS rates were 62% (95% CI: 56-68) and 64% (95% CI: 57-70) for patients with ER-positive disease treated or not with adjuvant chemotherapy ( Figure 3B ). It is of note that ER expression was not predictive for the efficacy of adjuvant chemotherapy in the Oxford Overview [1] . In this latter report, ER positivity was defined either as an ER expression >1% by IHC or >10 fmol/mg by ligandbinding assay. We hypothesized that the apparent discrepancy between Oxford meta-analysis and our results could be due to differences in the methods and cut-off used to define ER positivity. We therefore compared predictive values of ER expression when assessed by ligand-binding assay (10 fmol/mg protein cut-off) and by IHC (10% cut-off) in patients for whom both expressions were available (n = 702). As reported in Table 3 , while ER expression by IHC was predictive in this population (test for interaction, P = 0.002), ER expression assessed by ligand-binding assay was not predictive for the efficacy of adjuvant chemotherapy (test for interaction, P = 0.20). The performance of adjuvant chemotherapy was associated with hazard ratio for relapse or death at 1.10 (95% CI: 0.82-1.47) and 0.89 (95% CI: 0.69-1.14) in patients with ER+ disease defined by IHC and ligand-binding assay, respectively. predictive value of Her2 status and of molecular subclasses regarding the benefit of adjuvant chemotherapy As reported in Table 2 , Her2 status was not predictive for the benefit of adjuvant anthracyclines-based chemotherapy for DFS (test for interaction, P = 0.37). The performance of chemotherapy was associated with an adjusted hazard ratio for relapse or death of 0.64 (95% CI: 0.35-1.17) for patients with Her2-expressing tumors and 0.86 (95% CI: 0.68-1.10) for patients whose tumor did not express Her2. When included in a Cox model adjusted for the clinical characteristics and the ER by treatment interaction, the Her2 by treatment interaction was not significant, indicating that Her2 did not significantly add a predictive value to that provided by the ER status for DFS (P = 0.89).
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As reported in Table 2 , the breast cancer molecular subclassification significantly predicted the efficacy of chemotherapy (test for interaction, P = 0.01). The performance of adjuvant chemotherapy was associated with an adjusted hazard ratio for relapse or death of 0.42 (95% CI: 0.17-1.05) for patients with Her2+/ER2 tumors, 0.54 (95% CI: 0.27-1.08) for those with basal-like tumors, 0.35 (95% CI: 0.18-0.68) for patients with Her22/ER2/nonbasal tumors and 1.07 (95% CI: 0.81-1.41) for patients with luminal-like tumors. Nevertheless, when included in a Cox model adjusted for the clinical characteristics and the ER by treatment interaction, the molecular subclassification did not significantly add a predictive value to that provided by the ER status for DFS (P = 0.32).
discussion
Based on data reported in DNA array [5] [6] [7] and IHC [8] [9] [10] studies, we used four biomarkers i.e. ER, Her2, EGFr and CK 5/6 to define molecular subclasses. Several issues could be discussed regarding this definition. First, EGFr and CK 5/6 stainings, but not PgR, were used to classify basal-like tumors. We applied the approach from Nielsen et al. [8] who showed, based on DNA array and immunostainings, that four biomarkers i.e. Her2, ER, EGFr and CK 5/6 may accurately classify basal-like tumors. The second issue is the emergence of a subclass defined as Her22/ER2/nonbasal tumors. This tumor subclass, while ER2 by IHC, exhibits both luminal features (including CK 18 expression) and characteristics of aggressiveness, such as younger age and higher tumor grade, as compared to luminal-like tumors. Studies that focused on breast cancer classification using large-scale genomic analyses have already reported that some luminal-like breast cancers, i.e. luminal type B [7] , could present a more aggressive phenotype including high tumor grade [5] [6] [7] . 
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We found that ER expression was a strong and independent predictive biomarker for the benefit of adjuvant chemotherapy ( Table 2 ). Although the concept that chemotherapy is less effective in ER-positive disease has become popular, there is actually no reported solid evidence based on interaction tests that ER expression is truly predictive of the benefit of adjuvant anthracycline-based chemotherapy. For instance, in the last published Oxford meta-analysis, the test for heterogeneity was not significant [1] . In addition, several randomized trials have reported recently that chemotherapy could improve outcome in ER-positive disease [25, 26] . However, it must be emphasized that ER determination in most of the previously cited trials were based on either ligandbinding assay with a conventional cut-off at 10 fmol/mg or a 1% cut-off for IHC positivity, while a number of teams currently use a 10% cut-off in their daily practice for decision making. In our study, while ER expression determined by IHC (10% cut-off) was predictive (P = 0.002), ER expression determined by ligand-binding assay in the same patient subset was not (P = 0.20). This data indicated that the apparent discrepancy between Oxford meta-analysis and present results could be due to difference in technologies and cut-off. This finding, if confirmed in further studies, may have some implications regarding the selection of patients for adjuvant chemotherapy in the future.
Several studies have reported that Her2 status, when determined by IHC, could be predictive for the benefit of adjuvant anthracycline-based chemotherapy [15] [16] [17] [18] . Our study found that the P value for interaction between Her2 expression and benefit of chemotherapy was 0.37, and showed that Her2 did not add predictive information to that provided by the ER status. Several hypotheses can be put forward to explain this apparent discrepancy. The first explanation may be related to the limited statistical power of our study, which does not allow excluding a potential interaction with a higher number of events. A second explanation could be related to the tested hypothesis in the trial design. Studies that reported a positive interaction compared an adjuvant anthracycline-based regimen [15, 18] with another chemotherapy, while our study compared an anthracycline-based chemotherapy with no treatment. Since it has been reported that erbb2 gene coamplifies with TOP2A gene [27] , the target of anthracyclines, one could hypothesize that Her2 status predicts more specifically the benefit of anthracyclines over another chemotherapy regimen, while ER status could predict more adequately the benefit of chemotherapy over a no-treatment arm.
We analyzed then whether a new molecular subclassification could be predictive for the effect of adjuvant chemotherapy. It has been reported previously that molecular subclassification was associated with efficacy of preoperative chemotherapy [19] . Nevertheless, when compared with conventional predictors (ER and tumor grade), the molecular subclassification added little information to predict the pathological complete response rates. In the present study, while the molecular subclassification was predictive for the efficacy of chemotherapy (test for interaction, P = 0.01, Table 2 ), its determination did not add significant information to the predictive value provided by the ER status (P = 0.32).
Although this study showed strong evidence that ER IHC with a 10% cut-off is predictive for the benefit of anthracyclinebased chemotherapy, it suffers from some limitations that hamper a transfer into clinical practice. First, the ER determination was based on tissue array and not on conventional tissue sections. While the correlation between tissue array and tissue sections has been reported to be excellent [28] , a validation using the daily technology may still be required. Secondly, the chemotherapy regimen used in our study included moderate doses of epirubicin in most of the patients. Since it has been shown that higher doses of epirubicin improves outcome [29] , we cannot recommend withholding adjuvant anthracyclines based on our data. Thirdly, although there is a significant interaction between ER expression and benefit of adjuvant anthracycline-based chemotherapy, our study does not have the statistical power to exclude a potential moderate benefit for adjuvant chemotherapy in patients with ER-positive disease.
In conclusion, our study indicates that ER expression strongly predicts the efficacy of adjuvant chemotherapy, but did not show that Her2 or molecular subclassification provide additional information as compared with ER status to predict efficacy of adjuvant chemotherapy over a no-treatment arm. 
